Servier Acquires Potential Fragile X Syndrome Treatment KER-0193
AI-Generated Summary
Servier has acquired KER-0193 from Kaerus Bioscience, a novel small molecule with potential to treat Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder. KER-0193 has received Orphan Drug and Rare Pediatric Drug Designations from the U.S. FDA and successfully completed Phase 1 trials. This acquisition significantly strengthens Servier's neurology pipeline, aligning with its 2030 strategy to address unmet needs in rare diseases. A Phase 2 clinical trial for KER-0193 in FXS patients is planned for 2026 in America and Europe.
In a nutshell
This acquisition represents a significant step in addressing a high unmet medical need for patients with Fragile X syndrome, a condition currently lacking approved therapies. It also underscores Servier's strategic expansion into neurodevelopmental disorders and rare diseases, signaling a broader industry trend towards targeted treatments for genetic conditions.
Source: The Manila Times
